Skip to main content
Toggle navigation
Live markets
Search
Search
Search
Search
My profile
My Subscriptions
Watchlists
Quote alerts
Create account
Sign in
EN
FR
EN
PT
NL
NB
DE
IT
Home
Company Press Releases
Company press releases
Subscribe
Filters
Filters
Refresh
Reset
Icon After
Date
Toggle Visibility
All
Today
This week
This month
Custom date range
From
To
Topic
Toggle Visibility
Acquisition or disposal of the issuer’s own shares
Additional regulated information required to be disclosed under the laws of a Member State
Adjustment of interest rate
Alliances and agreements
Annual financial and audit Reports
Change in Capital
Changes in the rights attaching to the classes of shares or securities
Commercial operations
Commercial results
Corporate life
Dividend
Ex Date
General meeting / Board Meeting
Half yearly financial reports and audit reports/limited reviews
Home Member State
Income
Inside information
Joint venture
Journal / appointments
Legal
Major shareholding notifications
Mandatory notification of trade primary insiders
Meetings / events
Mergers, Acquiqitions, Transferts
New
New establishment
News contracts
Non-regulatory press releases
Other financial transaction
Other subject
Payments to governments
Polls / Surveys
Products and services
Prospectus / admission document
Rating
Sales
Share history
Share introduction and issues
Takeover bids
Total number of voting rights and capital
Trends / Analyses
Provider
Toggle Visibility
ActusNewsWire
BusinessWire
EQS Group
Euronext
GlobeNewswire
Les Echos
Marketwire
Modular Finance
Oslo Børs Newspoint
PR Newswire
Displaying 51 - 75 of 75 results
Released
Company
Title
Industry
Topic
23 Dec 2021
08:30 CET
PHARNEXT
Experienced Pharmaceutical Industry Executive Dr. Elisabeth Svanberg Appointed as Chairman of Pharnext Board of Directors
20103010 Biotechnology
Corporate life
22 Dec 2021
19:30 CET
PHARNEXT
Pharnext and Global Tech Opportunities 13 Agree to Stop Convertible Bond Program from End of May 2022
20103010 Biotechnology
Other financial transaction
22 Dec 2021
19:30 CET
PHARNEXT
Pharnext et Global Tech Opportunities 13 ont conclu un accord prévoyant l'arrêt du financement par voie d'obligations convertibles à partir de la fin mai 2022
20103010 Biotechnology
Other financial transaction
21 Dec 2021
08:30 CET
PHARNEXT
Pharnext: Tirage d'une sixième tranche de 300 obligations convertibles en actions
20103010 Biotechnology
Legal
22 Nov 2021
18:00 CET
PHARNEXT
Pharnext nomme le Dr Burkhard Blank au poste de Directeur Médical et Responsable de la Recherche et du Développement
20103010 Biotechnology
Corporate life
22 Nov 2021
18:00 CET
PHARNEXT
Pharnext appoints Dr. Burkhard Blank as new Chief Medical Officer and Head of Research & Development
20103010 Biotechnology
Corporate life
12 Nov 2021
18:00 CET
PHARNEXT
Pharnext: Tirage d'une cinquième tranche de 300 obligations convertibles en actions & Nombre total d'actions en circulation et droits de vote
20103010 Biotechnology
Legal
21 Oct 2021
08:30 CEST
PHARNEXT
Pharnext confirms details for 2021 Hybrid Research & Development Day
20103010 Biotechnology
Corporate life
21 Oct 2021
08:30 CEST
PHARNEXT
Pharnext précise l'agenda de l'édition 2021 de ses journées dédiées à ses activités de recherche et développement
20103010 Biotechnology
Corporate life
19 Oct 2021
08:30 CEST
PHARNEXT
Pharnext renforce son équipe de direction avec trois nominations clés pour poursuivre le développement de PXT3003 jusqu'à sa mise sur le marché
20103010 Biotechnology
Corporate life
19 Oct 2021
08:30 CEST
PHARNEXT
Pharnext strengthens its management team with three key appointments to support ongoing development of PXT3003 toward approval and commercialization
20103010 Biotechnology
Corporate life
18 Oct 2021
18:00 CEST
PHARNEXT
Pharnext: Les données de la première étude clinique de Phase III de PXT3003 dans la maladie de Charcot-Marie-Tooth de type 1A, l'essai PLEO-CMT, publiées dans l'Orphanet Journal of Rare Diseases.
20103010 Biotechnology
Corporate life
18 Oct 2021
18:00 CEST
PHARNEXT
Pharnext: Data from First Phase III Clinical Study of PXT3003 in Charcot-Marie-Tooth Disease Type 1A, the PLEO-CMT Trial, Published in the Orphanet Journal of Rare Diseases
20103010 Biotechnology
Corporate life
14 Oct 2021
20:00 CEST
PHARNEXT
Pharnext annonce ses résultats financiers du 1er semestre 2021
20103010 Biotechnology
Income
14 Oct 2021
20:00 CEST
PHARNEXT
Pharnext Reports First Half 2021 Financial Results
20103010 Biotechnology
Income
06 Oct 2021
08:30 CEST
PHARNEXT
Pharnext to Host 2021 Hybrid Research & Development Day
20103010 Biotechnology
Meetings / events
06 Oct 2021
08:30 CEST
PHARNEXT
Pharnext organise l'édition 2021 de ses journées dédiées à ses activités de recherche et développement
20103010 Biotechnology
Meetings / events
15 Jul 2021
18:00 CEST
PHARNEXT
Piers Morgan rejoint le Conseil d'Administration de Pharnext
20103010 Biotechnology
General meeting / Board Meeting
15 Jul 2021
18:00 CEST
PHARNEXT
Piers Morgan Joins Pharnext's Board of Directors
20103010 Biotechnology
General meeting / Board Meeting
12 Jul 2021
08:00 CEST
PHARNEXT
Pharnext Announces First Patient Enrolled in Europe in the PREMIER Trial, its Pivotal Phase III Clinical Study of PXT3003 in Charcot-Marie-Tooth Disease Type 1A ('CMT1A')
20103010 Biotechnology
Corporate life
12 Jul 2021
08:00 CEST
PHARNEXT
Pharnext annonce l'inclusion du premier patient en Europe dans l'essai PREMIER, son étude clinique pivot de Phase III de PXT3003 dans la maladie de Charcot-Marie-Tooth de type 1A (CMT1A)
20103010 Biotechnology
Corporate life
21 Jun 2021
08:30 CEST
PHARNEXT
Pharnext: Lettre aux Actionnaires
20103010 Biotechnology
Corporate life
21 Jun 2021
08:30 CEST
PHARNEXT
Pharnext: Shareholder Letter
20103010 Biotechnology
Corporate life
07 Jun 2021
08:00 CEST
PHARNEXT
Pharnext annonce le lancement d'un programme de financement par obligations convertibles d'un montant nominal maximum brut de 81 millions d'euros
20103010 Biotechnology
Other financial transaction
07 Jun 2021
08:00 CEST
PHARNEXT
Pharnext Announces a New Financing Through a Convertible Bond Program for a Total Amount up to €81 Million Gross to Extend its Cash Runway and to Continue to Fund its Pivotal Phase III Study
20103010 Biotechnology
Other financial transaction
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Pagination
«
« First
‹
‹‹
1
2
Company press releases subscription
×
To subscribe to Press releases from this issuer, visit the Subscription to Company news section in
your account
section or
create an account
.
Home
Markets
Amsterdam
Cash Products
Stocks
AEX index Stocks
AEX ESG Stocks
Indices
Funds
Bonds
ETFs
Structured products
Derivative products
Index options
Index futures
Stock options
Dividend derivatives
Stock futures
Quote Vendor Codes
Company regulated news
Latest
Archive
Brussels
Cash products
Stocks
Euronext regulated
Euronext Growth
Euronext Access
Expert Market
BEL 20 Stocks
Indices
Bonds
ETFs
Structured Products
Derivative products
Index futures
Stock options
Stock futures
Dividend derivatives
Quote Vendor Codes
Company regulated news
Latest
Archive
Expert Market
Dublin
Stocks
Euronext regulated
Euronext Growth
ISEQ 20 Stocks
Indices
Funds
Bonds
Irish Government Bonds
DOL
Lisbon
Cash Products
Stocks
Euronext regulated
Euronext Access
PSI Stocks
Indices
Bonds
Derivative products
Index futures
Stock futures
Dividend derivatives
Quote Vendor Codes
Company regulated news
Latest
Archive
Milan
Cash Products
Stocks
Euronext Milan
Euronext Growth Milan
Euronext Star Milan
Euronext Global Equity Market
EuroTLX
Trading After Hours
MIB ESG Stocks
Bonds
MOT
Euronext Access Milan
EuroTLX
Structured Products
SeDeX
EuroTLX
ETFs
Funds
Derivative products
All derivatives
Index futures
Index options
Stock options
Stock futures
Dividend derivatives
Quote Vendor Codes
IPOs
Oslo
Cash Products
Stocks
Oslo Børs
Euronext Growth
Euronext Expand
Top performers
OBX stocks
OBX ESG Stocks
OSEBX stocks
OSEFX Stocks
Seafood Stocks
Shipping Stocks
Equity indices
Bonds
Oslo Børs
Nordic Alternative Bond Market
Bond indices
ETFs
Funds
Derivatives
Derivative products
Quote Vendor Codes
Company regulated news
Latest
Archive
Financial calendars
Primary insiders
Paris
Cash Products
Stocks
Euronext regulated
Euronext Growth
Euronext Access
CAC 40 Stocks
CAC 40 ESG Stocks
Indices
Bonds
ETFs
Structured products
Derivative products
Index futures
Index options
Stock options
Stock futures
Dividend derivatives
Quote Vendor Codes
Company regulated news
Latest
Archive
Equities
All Markets directories
All Markets
Euronext regulated
Euronext Growth
Euronext Access
Euronext Expand
Euronext Global Equity Market
EuroTLX
Trading After Hours
Company regulated news
Latest
Archive
IPOs
All IPOs
Listing sponsors
Euronext Tech Leaders
Family business
Indices
Directory
ESG indices
Indices documents
Indices news
Index consultations
Contact Euronext indices
ETFs
Directory
ESG ETFs
Funds
Directory
ESG Funds
Oslo Mutual Funds
Fixed Income
ESG Bonds
1.5° Bonds
All Markets directories
All Markets
Amsterdam
Brussels
Dublin
Lisbon
Oslo
Milan
Paris
Structured Products
Directory / search
Bid-Only trading status
Trading Turbos in the Netherlands
Equity Derivatives
Index Futures
Index Options
Stock Options
Stock Futures
Dividend Derivatives
ETF Options
Contracts specifications
Tick Sizes
Wholesale Trading
Quote vendor codes
Commodities
Quotes
Quotes snapshot
Milling Wheat futures
Rapeseed futures
Corn futures
European Durum Wheat Futures
Milling Wheat options
Rapeseed options
Corn options
Trading calendars
Delivery
Wholesale Trading
Commitments of Traders (CoT) report
Contracts specifications
Quote vendor codes
Knowledge Centre
Bid & Ask
Options Investing E-learning
Contract Specifications
Position Management
Intrinsic Value
Premium & Valuation
Moneyness
Positions
Euronext News
Resources
Statistics & reports
Quality of execution
Trading hours & Holidays
Contract specifications
Quote vendor codes
Key Information Document
Class level
Product group level
Notices / Corporate actions
Cash Notices / Corporate actions
Derivatives corporate actions
All Corporate Actions
Latest
Unusual Contract Sizes, Dividends
Corporate Action Services
Corporate Action Policies
Derivatives notices
Market events
Suspended instruments
Stressed Market Conditions
Breach of Double Cap limits
Exceptional Market Conditions
Miscellaneous short messages
Market status
Members list
Issuers compliance
Where to find